EKSO (Ekso Bionics Holdings) LT-Debt-to-Total-Asset: 0.03 (As of Mar. 2026)

What is Ekso Bionics Holdings LT-Debt-to-Total-Asset?

Ekso Bionics Holdings EKSO -0.42% 32 LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.38 (Significantly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ekso Bionics Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.03.

Ekso Bionics Holdings's long-term debt to total assets ratio declined from Mar. 2025 (0.14) to Mar. 2026 (0.03). It may suggest that Ekso Bionics Holdings is progressively becoming less dependent on debt to grow their business.

Ekso Bionics Holdings (NAS:EKSO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ekso Bionics Holdings LT-Debt-to-Total-Asset Related Terms

Ekso Bionics Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ekso Bionics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ekso Bionics Holdings LT-Debt-to-Total-Asset Chart

Ekso Bionics Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.12

0.19

0.16

0.05

Ekso Bionics Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.14	0.16	0.06	0.05	0.03

32GF Score

Ekso Bionics Holdings Inc EKSO

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ekso Bionics Holdings LT-Debt-to-Total-Asset Calculation

Ekso Bionics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.945	/	20.111
	=	0.05

Ekso Bionics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.641	/	19.668
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

Ekso Bionics Holdings (EKSO) has a LT-Debt-to-Total-Asset of 0.03 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ekso Bionics Holdings and its competitors.

Is Ekso Bionics Holdings' LT-Debt-to-Total-Asset too high?

Ekso Bionics Holdings' current LT-Debt-to-Total-Asset is 0.03. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Ekso Bionics Holdings' LT-Debt-to-Total-Asset compare to POCI and HBIO?

Ekso Bionics Holdings' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ekso Bionics Holdings stock overvalued right now?

Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.38, compared to a current price of $11.65 — trading 166% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?

Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued. The current stock price of $11.65 is trading 166% above its estimated GF Value™ of $4.38. GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.

Key valuation signals for EKSO:

LT-Debt-to-Total-Asset: 0.03
GF Value™: $4.38 vs. price of $11.65 (166% above fair value)
GF Score™: 32/100 with 10 warning signs

No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ekso Bionics Holdings Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies POCI HBIO NEPH MLSS FEMY UEEC DXR RVP ZJYL RGNT ISRG XPAR:EL TSE:7741 BDX MDLN XSWX:ALC RMD WST TSE:4543 XPAR:DIM

Address 101 Glacier Point, Suite A, San Rafael, CA, USA, 94901

Website https://www.eksobionics.com

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

32GF Score

Get the complete analysis for EKSO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65

Price

$4.38

GF Value

View EKSO Analysis

See LT-Debt-to-Total-Asset data for all stocks →